?term=Needham M - Search Results

1

Type 1 diabetes, COVID-19 vaccines and short-term safety: Subgroup analysis from the global COVAD study.

Chatterjee T, Ravichandran N, Nair N, Gracia-Ramos AE, Barman B, Sen P, Joshi M, Saha S, Nune A, Pande AKR, Velikova T, Parodis I, Tan AL, Shinjo SK, Boro H, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group. Chatterjee T, et al. J Diabetes Investig. 2024 Jan;15(1):131-138. doi: 10.1111/jdi.14079. Epub 2023 Sep 11. J Diabetes Investig. 2024. PMID: 37697820 Free PMC article.

This study aimed to evaluate the frequency and severity of short-term (<7-day) adverse vaccination events (AEs) and their risk factors among type 1 diabetes patients. ...

This study aimed to evaluate the frequency and severity of short-term (<7-day) adverse vaccination events (AEs) and their risk fac …

2

Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study.

Doskaliuk B, Ravichandran N, Sen P, Day J, Joshi M, Nune A, Nikiphorou E, Saha S, Tan AL, Shinjo SK, Ziade N, Velikova T, Milchert M, Jagtap K, Parodis I, Gracia-Ramos AE, Cavagna L, Kuwana M, Knitza J, Chen YM, Makol A, Agarwal V, Patel A, Pauling JD, Wincup C, Barman B, Tehozol EAZ, Serrano JR, La Torre IG, Colunga-Pedraza IJ, Merayo-Chalico J, Chibuzo OC, Katchamart W, Goo PA, Shumnalieva R, Hoff LS, Kibbi LE, Halabi H, Vaidya B, Shaharir SS, Hasan ATMT, Dey D, Gutiérrez CET, Caballero-Uribe CV, Lilleker JB, Salim B, Gheita T, Chatterjee T, Distler O, Saavedra MA; COVAD study group; Chinoy H, Agarwal V, Aggarwal R, Gupta L. Doskaliuk B, et al. Rheumatol Int. 2023 Sep;43(9):1651-1664. doi: 10.1007/s00296-023-05345-y. Epub 2023 Jun 23. Rheumatol Int. 2023. PMID: 37351634 Free PMC article.

Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contribute to vaccine hesitancy. ...

Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contrib …

3

Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey.

Naveen R, Thakare DR, Kuwana M, Pauling JD, Day J, Joshi M, Parodis I, Sen P, Jagtap K, Nikiphorou E, Saha S, Agarwal V, Chatterjee T, Lilleker JB, Kardes S, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Tan AL, Nune A, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Distler O, Chinoy H; COVAD Study Group; Aggarwal R, Gupta L, Agarwal V, Makol A. Naveen R, et al. Rheumatol Int. 2023 Jul;43(7):1265-1275. doi: 10.1007/s00296-023-05310-9. Epub 2023 Mar 31. Rheumatol Int. 2023. PMID: 37000295 Free PMC article.

The safety profile of COVID-19 vaccines is understudied in patients with systemic sclerosis (SSc). We compared short-term adverse events (AEs) 7 days following vaccination in patients with SSc vs other rheumatic (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and heal …

The safety profile of COVID-19 vaccines is understudied in patients with systemic sclerosis (SSc). We compared short-term adverse eve …

4

Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys.

Sen P, R N, Houshmand N, Moghadam Kia S, Joshi M, Saha S, Jagtap K, Agarwal V, Nune A, Nikiphorou E, Tan AL, Shinjo SK, Ziade N, Velikova T, Milchert M, Parodis I, Gracia-Ramos AE, Cavagna L, Kuwana M, Knitza J, Makol A, Patel A, Pauling JD, Wincup C, Barman B, Zamora Tehozol EA, Rojas Serrano J, García-De La Torre I, Colunga-Pedraza IJ, Merayo-Chalico J, Chibuzo OC, Katchamart W, Akawatcharangura Goo P, Shumnalieva R, Chen YM, Hoff LS, El Kibbi L, Halabi H, Vaidya B, Sazliyana Shaharir S, Hasan ATMT, Dey D, Gutiérrez CET, Caballero-Uribe CV, Lilleker JB, Salim B, Gheita T, Chatterjee T, Distler O, Saavedra MA, Day J, Chinoy H; COVAD Study Group; Agarwal V, Aggarwal R, Gupta L. Sen P, et al. Rheumatology (Oxford). 2023 Oct 3;62(10):3291-3301. doi: 10.1093/rheumatology/kead057. Rheumatology (Oxford). 2023. PMID: 36734536 Free article.

Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) (OR: 0.26; 95% CI: 0.24, 0.30, P < 0.001). However, concerns/fear over long-term safety had increased (OR: 3.6; 95% CI: 2.9, 4.6, P < 0.01). ...CONCLUSION: Vaccine hesitancy has decreased from 2021 to

…

Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) (OR: 0.26; 95% CI: 0.24, 0.30, P < 0.001). However, concerns/fear over

…

5

COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis.

Naveen R, Parodis I, Joshi M, Sen P, Lindblom J, Agarwal V, Lilleker JB, Tan AL, Nune A, Shinjo SK, Salim B, Ziade N, Velikova T, Edgar Gracia-Ramos A, Saavedra MA, Day J, Makol A, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L, Nikiphorou E; COVAD Study Group. Naveen R, et al. Rheumatology (Oxford). 2023 Jul 5;62(7):2366-2376. doi: 10.1093/rheumatology/keac624. Rheumatology (Oxford). 2023. PMID: 36315075 Free article.

OBJECTIVES: The COVID-19 vaccination in autoimmune diseases (COVAD) study aimed to assess short-term COVID-19 vaccination-related adverse events (AEs) in RA patients. ...

OBJECTIVES: The COVID-19 vaccination in autoimmune diseases (COVAD) study aimed to assess short-term COVID-19 vaccination-related adv …

6

Higher risk of short term COVID-19 vaccine adverse events in myositis patients with autoimmune comorbidities: results from the COVAD study.

Dey M, R N, Nikiphorou E, Sen P, Saha S, Lilleker JB, Agarwal V, Kardes S, Day J, Milchert M, Joshi M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Selva O'Callaghan A, Kim M, Chatterjee T, Tan AL, Makol A, Nune A, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Distler O, Barman B, Singh YP, Ranjan R, Jain A, Pandya SC, Pilania RK, Sharma A, Manoj MM, Gupta V, Kavadichanda CG, Patro PS, Ajmani S, Phatak S, Goswami RP, Chowdhury AC, Mathew AJ, Shenoy P, Asranna A, Bommakanti KT, Shukla A, Pande AR, Chandwar K, Pauling JD, Wincup C, Üsküdar Cansu D, Zamora Tehozol EA, Rojas Serrano J, García-De La Torre I, Del Papa N, Sambataro G, Fabiola A, Govoni M, Parisi S, Bartoloni Bocci E, Sebastiani GD, Fusaro E, Sebastiani M, Quartuccio L, Franceschini F, Sainaghi PP, Orsolini G, De Angelis R, Danielli MG, Venerito V, Traboco LS, Hoff LS, Kusumo Wibowo SA, Tomaras S, Langguth D, Limaye V, Needham M, Srivastav N, Yoshida A, Nakashima R, Sato S, Kimura N, Kaneko Y, Loarce-Martos J, Prieto-González S, Gil-Vila A, Gonzalez RA, Chinoy H, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group. Dey M, et al. Among authors: needham m. Rheumatology (Oxford). 2023 May 2;62(5):e147-e152. doi: 10.1093/rheumatology/keac603. Rheumatology (Oxford). 2023. PMID: 36282492 Free PMC article. No abstract available.

7

COVAD survey 2 long-term outcomes: unmet need and protocol.

Fazal ZZ, Sen P, Joshi M, Ravichandran N, Lilleker JB, Agarwal V, Kardes S, Kim M, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Nikiphorou E, Tan AL, Chatterjee T, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Selva-O'Callaghan A, Nune A, Knitza J, Kuwana M, Gutiérrez CT, Caballero-Uribe CV, Dey D, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group. Fazal ZZ, et al. Rheumatol Int. 2022 Dec;42(12):2151-2158. doi: 10.1007/s00296-022-05157-6. Epub 2022 Aug 14. Rheumatol Int. 2022. PMID: 35964271 Free PMC article.

Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing poten …

Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset …

8

Observation of the Decay Λ_{b}^{0}→Λ_{c}^{+}τ^{-}ν[over ¯]_{τ}.

Aaij R, Abdelmotteleb ASW, Beteta CA, Abudinén F, Ackernley T, Adeva B, Adinolfi M, Afsharnia H, Agapopoulou C, Aidala CA, Aiola S, Ajaltouni Z, Akar S, Albrecht J, Alessio F, Alexander M, Albero AA, Aliouche Z, Alkhazov G, Cartelle PA, Amato S, Amey JL, Amhis Y, An L, Anderlini L, Andersson M, Andreianov A, Andreotti M, Archilli F, Artamonov A, Artuso M, Arzymatov K, Aslanides E, Atzeni M, Audurier B, Bachmann S, Bachmayer M, Back JJ, Rodriguez PB, Balagura V, Baldini W, Baptista de Souza Leite J, Barbetti M, Barlow RJ, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Basels JM, Bashir S, Bassi G, Batsukh B, Battig A, Bay A, Beck A, Becker M, Bedeschi F, Bediaga I, Beiter A, Belavin V, Belin S, Bellee V, Belous K, Belov I, Belyaev I, Bencivenni G, Ben-Haim E, Berezhnoy A, Bernet R, Berninghoff D, Bernstein HC, Bertella C, Bertolin A, Betancourt C, Betti F, Bezshyiko I, Bhasin S, Bhom J, Bian L, Bieker MS, Biesuz NV, Bifani S, Billoir P, Biolchini A, Birch M, Bishop FCR, Bitadze A, Bizzeti A, Bjørn M, Blago MP, Blake T, Blanc F, Blusk S, Bobulska D, Boelhauve JA, Garcia OB, Boettcher T, Boldyrev A, Bondar A, Bondar N, Borghi S, Borisyak M, Borsato M, Borsuk JT, Bouchiba SA, Bowcock… See abstract for full author list ➔ Aaij R, et al. Among authors: needham m. Phys Rev Lett. 2022 May 13;128(19):191803. doi: 10.1103/PhysRevLett.128.191803. Phys Rev Lett. 2022. PMID: 35622037 Free article.

The ratio of semileptonic branching fractions R(lambda_{c}^{+})B(lambda_{b}^{0}lambda_{c}^{+}tau^{-}nu[over ]_{tau})/B(lambda_{b}^{0}lambda_{c}^{+}mu^{-}nu[over ]_{mu}) is derived to be 0.2420.0260.0400.059, where the external branching fraction uncertainty from the channel lambd …

The ratio of semileptonic branching fractions R(lambda_{c}^{+})B(lambda_{b}^{0}lambda_{c}^{+}tau^{-}nu[over ]_{tau})/B(lambda_{b}^{0}lambda_ …

9

Idiopathic inflammatory myopathies: a review.

Ashton C, Paramalingam S, Stevenson B, Brusch A, Needham M. Ashton C, et al. Among authors: needham m. Intern Med J. 2021 Jun;51(6):845-852. doi: 10.1111/imj.15358. Intern Med J. 2021. PMID: 34155760 Review.

Idiopathic inflammatory myopathy (IIM) is the umbrella term including dermatomyositis (DM), polymyositis (PM), overlap myositis (OM), sporadic inclusion body myositis (IBM) and necrotising autoimmune myopathy (NAM), also known as immune-mediated necrotising myopathy. There …

Idiopathic inflammatory myopathy (IIM) is the umbrella term including dermatomyositis (DM), polymyositis (PM), overlap myositis (OM), …

10

Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.

Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tankó LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Zhang Auberson L; RESILIENT Study Extension Group. Amato AA, et al. Among authors: needham m. Neurology. 2021 Mar 23;96(12):e1595-e1607. doi: 10.1212/WNL.0000000000011626. Epub 2021 Feb 17. Neurology. 2021. PMID: 33597289 Free PMC article. Clinical Trial.

OBJECTIVE: To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM). ...CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with sIBM, long-term treatment with bimagrumab was saf …

OBJECTIVE: To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM). ...CLASS …

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13 results

Search Page